Transplant News and Research RSS Feed - Transplant News and Research

Study: Older adults with high blood pressure appear to have good kidney health after donation

Study: Older adults with high blood pressure appear to have good kidney health after donation

With proper monitoring, kidney donation may be safe for individuals with high blood pressure, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The study found that while hypertension can have negative effects on the kidneys, older adults with the condition appear to have good kidney health following donation. [More]
Findings show effective treatment for type 1 diabetes patients with severe hypoglycemia

Findings show effective treatment for type 1 diabetes patients with severe hypoglycemia

Type 1 diabetes (T1D) patients who have developed low blood sugar (hypoglycemia) as a complication of insulin treatments over time are able to regain normal internal recognition of the condition after receiving pancreatic islet cell transplantation, according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania, published online in Diabetes. [More]
CF patients require close monitoring for resistance to ganciclovir after lung transplantation

CF patients require close monitoring for resistance to ganciclovir after lung transplantation

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation. [More]
Baylor Scott & White Health forms alliance with Cleveland Clinic

Baylor Scott & White Health forms alliance with Cleveland Clinic

Baylor Scott & White Health today announces an alliance with Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute. [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
Study: Low glycemic diet does not improve insulin sensitivity or cardiovascular risk factors

Study: Low glycemic diet does not improve insulin sensitivity or cardiovascular risk factors

Nutrition experts are continually debating the nutritional value of carbohydrate-containing foods and whether some are healthier than others. High carbohydrate foods are classified by how much they increase blood sugar; known as glycemic index. In new findings led by researchers at Brigham and Women's Hospital in Boston and Johns Hopkins University in Baltimore, researchers looked at glycemic index' effect on cardiovascular disease (CVD) and diabetes and found that low glycemic diets did not improve insulin sensitivity or cardiovascular risk factors. [More]
Two studies shed new light on risks associated with blood transfusions

Two studies shed new light on risks associated with blood transfusions

Two studies published in the January issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, shed new light on the prevalence of transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO), the number one and two leading causes of blood transfusion-related deaths in the United States. [More]
Simple assessments can help prevent risk of passing Ebola virus disease from organ donor

Simple assessments can help prevent risk of passing Ebola virus disease from organ donor

While serious infections can be transmitted from donated organs, the risk of passing Ebola virus disease from an organ donor to a recipient is extremely small. In a new editorial published in the American Journal of Transplantation, experts explain how simple assessments of donors can help ensure that the organ supply is safe, while having little impact on the donor pool. [More]
Novel marker may help doctors choose most effective treatment for older patients with AML

Novel marker may help doctors choose most effective treatment for older patients with AML

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). [More]
Apheresis: A potent therapeutic in extracorporeal photopherisis

Apheresis: A potent therapeutic in extracorporeal photopherisis

Apheresis, the simple process of drawing blood, becomes a powerful therapeutic in extracorporeal photopherisis (ECP) according to clinicians and scientists who met at the NIH State of the Science Symposium in Therapeutic Apheresis. Nora Ratcliffe, MD, of Dartmouth Hitchcock, looked at current methodology and opportunities for research in a paper recently published in Transfusion Medicine Review, titled "National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis." [More]
Stem cells from healthy eye could one day be used to repair scarred cornea

Stem cells from healthy eye could one day be used to repair scarred cornea

Treating the potentially blinding haze of a scar on the cornea might be as straightforward as growing stem cells from a tiny biopsy of the patient's undamaged eye and then placing them on the injury site, according to mouse model experiments conducted by researchers at the University of Pittsburgh School of Medicine. [More]
CUMC researchers devise way to replace torn knee meniscus

CUMC researchers devise way to replace torn knee meniscus

Columbia University Medical Center researchers have devised a way to replace the knee's protective lining, called the meniscus, using a personalized 3D-printed implant, or scaffold, infused with human growth factors that prompt the body to regenerate the lining on its own. [More]
Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). [More]
Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Ponatinib ‘superior’ to sequential second-generation TKI treatment in CML

Patients with chronic myelogenous leukaemia resistant or intolerant to at least one second-generation tyrosine kinase inhibitor have a higher probability of achieving a response to the third-generation TKI ponatinib than to a further second-generation TKI, research indicates. [More]
Cardiac monitoring foretells clinical deterioration in PAH

Cardiac monitoring foretells clinical deterioration in PAH

Monitoring right ventricular parameters can give advance warning of clinical deterioration in stable patients with idiopathic pulmonary arterial hypertension, research suggests. [More]

Unheated high tunnels help bedding plants growers reduce energy costs

Energy costs account for one of the largest expenses in commercial greenhouse production of annual bedding plants. Naturally, bedding plant producers are searching for more energy-efficient production methods that can reduce fuel usage and increase profits. Christopher Currey, Roberto Lopez, and Neil Mattson published a study in HortTechnology that gives growers in northern latitudes valuable information on finishing practices for annual bedding plants. [More]
Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing Phase II clinical study with its lead product ATIR. [More]
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand. [More]
Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco. [More]